Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LANCET: Apatinib with Neoadjuvant Chemotherapy in Early TNBC
NCT03243838Phase 2Completed
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Aug 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in triple-negative breast cancer (TNBC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Pathological Complete Response Rate at 24 weeks. Started Aug 2018; status: completed.
02
Drugs
Rivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03243838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243838.